Non-invasive Future RSP Systems focuses on non-invasive glucose sensing with a mission to touch virtually everyone, presenting a broad potential addressable market in digital health and diabetes monitoring that sales teams can target across hospitals, clinics, and consumer health channels.

Strategic Partnerships Recent and ongoing collaborations with Brenmiller Energy, Trumpf, and other partners indicate a channel and technology co-development approach. This creates sales opportunities through distribution agreements, system integrations, and bundled solutions for North America and EU markets.

EU Funding leverage EU Horizon 2020 backing and substantial prior equity funding demonstrate validated R&D progress and credibility with regulatory-compliant, grant-supported projects, which can help in joint funding pitches and reduce customer risk in pilot deployments.

Emerging Device Portfolio Development of Raman-based devices and wearable glucose sensors suggests multiple product lines for B2B and B2C channels, enabling sales teams to pitch cross-sell opportunities to medical device distributors, clinics, and health-tech integrators.

Early-Stage Revenue Current revenue is under one million with substantial funding totals, indicating a buyer-ready focus on pilots and proof-of-concept deployments to validate performance, allowing SDRs to target early adopters in healthcare and research institutions seeking innovative monitoring solutions.